Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130737 · ClinicalTrials.gov registry record · NA
TORUS 2 IDE Clinical Study
A NA study of Peripheral Arterial Disease, sponsored by Endologix.
- Active
- Registry status
- NA
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT04130737: Active NA study of Peripheral Arterial Disease, sponsored by Endologix.
NCT04130737 is a NA study of Peripheral Arterial Disease that is active but no longer recruiting, run by Endologix. The registered enrollment target is 188 participants, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04130737, a NA study of Peripheral Arterial Disease, is active but no longer recruiting, sponsored by Endologix.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the TORUS 2 IDE Clinical Study is to evaluate the safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA or the superficial femoral and/or proximal popliteal arteries.
Primary Outcome
An MAE is defined as all-cause death, target limb major amputation and clinically-driven target lesion revascularization (CD-TLR)
Conditions Studied
Interventions
- DEVICE TORUS Stent Graft System
Study Locations (20)
Arizona
- Southwest CVA - Mesa
- Vascular Heart & Lung Associates - Mesa
- Phoenix Cardiovascular Research Group - Phoenix
- Yuma Cardiology Associates - Yuma
Florida
- First Coast Cardiovascular Institute - Jacksonville
- Palm Vascular Centers - Miami Beach
- Coastal Vascular & Interventional - Pensacola
- Florida Cardiology - Winter Park
Michigan
- McLaren Bay Region - Bay City
- Michigan Vascular Center - Flint
- Eastlake Cardiovascular - Roseville
California
- Bay Area Vein & Vascular Institute - Burlingame
- UCSF - San Francisco
Arkansas
- Arkansas Heart - Little Rock
Colorado
- Rocky Mountain Regional VAMC - Aurora
Connecticut
- The Vascular Experts - Darien
Illinois
- AMITA Health - Elk Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2019-10-31 |
| Est. Completion | 2024-12-24 |
| Phase | NA |
What the registry record for NCT04130737 still lists
NCT04130737 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 4,204-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention - of which TORUS Stent Graft System is the first listed.
NCT04130737 names 20 study sites across 11 states, led by Arizona, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT04130737 about?
NCT04130737 is a clinical study titled "TORUS 2 IDE Clinical Study". The primary objective of the TORUS 2 IDE Clinical Study is to evaluate the safety and effectiveness of the TORUS Stent Graft System in the treatment of obstructive atherosclerotic lesions of the native SFA or the superficial femoral and/or proximal popliteal arteries.
What is the current status of trial NCT04130737?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 188 participants. The study started on 2019-10-31. Estimated completion is 2024-12-24.
What conditions does trial NCT04130737 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT04130737?
The interventions under investigation include: TORUS Stent Graft System (DEVICE).
Who is sponsoring clinical trial NCT04130737?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04130737 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04130737's enrollment target sits among peer trials
188 26th of 79 higher than 54 of 79 other Peripheral Arterial Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
Ultrasound Perfusion Estimation for Assessment of Peripheral Arterial Disease
RECRUITING · NA
-
Prehabilitation and Rehabilitation in PAD
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
Assessment of the Utility of the Pantheris Small Vessel (SV) System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI